Introduction
============

Erectile dysfunction (ED), the inability to develop or maintain sufficient erection, is widespread globally, and in developed countries.[@b1-dddt-9-6129] Recent studies have shown that the prevalence of ED is \>40% in Arab countries; this high prevalence is linked to several risk factors, including aging, obesity, lack of exercise, smoking, and the complications of diabeties mellitus.[@b2-dddt-9-6129] Vardenafil (VRD), a 5-phosphodiesterase (PDE5) inhibitor that blocks the enzyme in the smooth muscle cells that line the blood vessels supplying the corpus cavernosum of the penis, is one of the drugs of choice for the treatment of ED. Inhibition of PDE5 relaxes the blood vessels and increases the blood flow, resulting in an erection in response to sexual stimulation.[@b3-dddt-9-6129] Although VRD has low oral bioavailability (15%), it has significant advantages compared with sildenafil and tadalafil, the most commonly used alternatives for the treatment of ED. VRD is a more selective inhibitor of PDE5 than tadalafil or sildenafil and is ten times more potent than sildenafil.[@b4-dddt-9-6129]--[@b6-dddt-9-6129] VRD is thus used at a lower dose than tadalafil or sildenafil to maintain penile erection, potentially resulting in fewer side effects as runny or stuffy nose, headache, dizziness, upset stomach, and back pain. The main reasons for the low oral bioavailability of VRD are extensive metabolism and low solubility; VRD is designated a class II drug according to Biopharmaceutical Classification System.[@b7-dddt-9-6129],[@b8-dddt-9-6129]

The use of lipid vesicles as transdermal drug delivery systems has attracted increasing attention in recent years.[@b9-dddt-9-6129] It is generally accepted, however, that conventional liposomes would be unsuitable for transdermal delivery of VRD, since drugs delivered in this way remain confined to the upper layer of stratum corneum.[@b10-dddt-9-6129]

The discovery of ethosomes by Touitou et al widened the possibilities for using lipid vesicles for transdermal drug delivery.[@b11-dddt-9-6129] Ethosomes are lipid vesicles incorporating relatively high concentrations of ethanol that were designed to deliver drugs across the skin layers. Although ethosomes show significantly higher transdermal flux compared with liposomes and transfersomes, the exact reasons for this remain unclear; the enhanced permeation into deeper skin layers and distribution into lipid bilayers have been postulated to result from the synergistic effects of phospholipids and a high ethanol concentration in the vesicules.[@b12-dddt-9-6129] In a previous study, in vitro skin permeation of an ethosomal formulation of zidovudine was shown to b \~24-fold higher than that of an aqueous solution of the drug.[@b13-dddt-9-6129]

Few attempts have been made to enhance the oral bioavailability of VRD; one of these is the development of an orodispersible tablet formulation.[@b14-dddt-9-6129] There remains, however, a need to enhance absorption and overcome the short duration of action of VRD. The aim of the present study was to improve the bioavailability of VRD by enhancing its solubility and to increase its duration of action. It was hoped that this could be achieved by incorporation of VRD into a nanosized lipid vesicular matrix. Application as a transdermal film would avoid first-pass metabolism in the liver and lower the dose needed to maintain an erection, potentially reducing side effects.

Materials and methods
=====================

Materials
---------

VRD was purchased from Jinlan Pharm-Drugs Technology Co., Ltd. (Hangzhou, People's Republic of China). [l]{.smallcaps}-α-Phosphatidylcholine (soya 95%) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Hydroxypropyl methylcellulose (HPMC) and cholesterol (CHO) were purchased from Sigma-Aldrich Chemical Company (St Louis, MO, USA). Potassium dihydrogen phosphate was procured from BDH Chemicals Ltd. (Poole, UK). All other chemicals and reagents used were of analytical grade.

Methodology
-----------

### Formulation of VRD nanoethosomes

VRD nanoethosomes (VRD-NE) were formulated using a thin-layer evaporation technique.[@b15-dddt-9-6129] Fifteen sets of experimental conditions were constructed using Statgraphics Plus, Version 4 (Manugistics Inc., Rockville, MD, USA), with a Box--Behnken factorial design. The independent variables were the following: % [l]{.smallcaps}-α-phosphatidylcholine (*X*~1~) to total lipids, [l]{.smallcaps}-α-phosphatidylcholine, and CHO; ultrasonication time in minutes (*X*~2~); and % ethanol in the hydration medium (*X*~3~). These preliminary studies provided a basis for selecting the levels of each variable in the formulation. The selected responses were mean particle size (*Y*~1~) and VRD encapsulation efficiency (EE) (*Y*~2~). Variables and measured responses of the design experiment are presented in [Table 1](#t1-dddt-9-6129){ref-type="table"}. The total lipid concentration was 3% (w/v) of the total weight of each formulation.

[l]{.smallcaps}-α-Phosphatidylcholine and drug were weighed in a round-bottom flask and dissolved in chloroform--methanol (1:1, v/v). The organic solvent was evaporated using a rotary evaporator (Büchi Rotavapor R-200; Büchi Labortechnik AG, Flawi, Switzerland), and traces of residual solvent were removed in a vacuum oven (Model 6505; Thermo Fisher Scientific, Waltham, MA, USA) overnight. The precipitated lipid film was resuspended in ethanol--water using different ethanol ratios ([Table 2](#t2-dddt-9-6129){ref-type="table"}). The produced vesicles were kept at room temperature for 2 hours to encapsulate the VRD and then ultrasonicated using a probe sonicator (VC750; Sonics, Newtown, CT, USA) at 2°C for different lengths of time.

### Formulation of optimized (VRD-NE) transdermal films

Based upon the previous trials for film formation, HPMC (1.5%, w/v) polymers were used as the film matrix to which the optimized formulation was added. The solution was stirred with a magnetic stirrer for 2 hours and then poured into a petri dish and maintained at 40°C in an oven until the solvent was completely evaporated. Two films are prepared, one using unprocessed VRD and the other using VRD-NE.

Characterization of VRD-NE
--------------------------

### Vesicle structural and surface morphology

A transmission electron microscope (CM12 TEM; Philips, Amsterdam, the Netherlands) was used to determine VRD-NE morphology. The optimized formulation was stained with an aqueous solution of phosphotungstic acid (1%, w/v) prior to use. The sample was examined using an accelerated voltage of 20 kV, with a magnification of ×4,000.

### Vesicle size analysis

The vesicle size of the optimized VRD-NE formulation was determined using Zetatrac (Microtrac, Montgomeryville, PA, USA) at 20°C. Each measurement was carried out in triplicate.

### Entrapment efficiency

Free VRD was determined indirectly by centrifugation at 20,000 rpm for 45 minutes at 8°C using a cooling centrifuge (laboratory centrifuge K30, Sigma, Osterode, Germany). An aliquot of the supernatant (500 µL) was diluted with aqueous HCl (0.1 N) and injected directly into a high-performance liquid chromatography (HPLC) instrument using the method described by Carlucci et al,[@b16-dddt-9-6129] with measurement at 230 nm. VRD EE was determined by [Equation 1](#fd1-dddt-9-6129){ref-type="disp-formula"}. $$\begin{array}{l}
\text{Encapsulation} \\
{\text{efficiency}(w/w,\%) = \frac{\text{Amount}\ \text{of}\ \text{VRD}\ \text{in}\ \text{the}\ \text{nano}\ \text{ethosomes}}{\text{Weight}\ \text{of}\ \text{VRD}\ \text{initially}\ \text{added}}} \\
\end{array}$$

### Ex vivo skin permeation studies

A Franz diffusion cell apparatus (Microette Plus; Hanson Research, Chatsworth, CA, USA) was used to assess the diffusion of prepared films. Skin (2 cm^2^ used as a membrane) was obtained from the abdominal region of male rats after hair removal. Each diffusion cell had a donor and receptor chamber, with a film placed between them. The receptor medium was phosphate-buffered saline (pH 7.2), the stirring rate was 400 rpm, and the temperature was maintained at 32°C±0.5°C. The autosampler collected aliquots at 0.5, 1, 2, 4, 8, 12, 24, and 36 hours, and these were then analyzed by HPLC. Skin permeation parameters, steady-state transdermal flux (*J*~ss~), diffusion coefficient (*D*), enhancement ratio (ER), and permeability coefficient (*K*~p~), were calculated from the in vitro skin permeation data. The cumulative amount of VRD permeated per unit area of skin was plotted as a function of time. *J*~ss~ and lag time were calculated from the slope and *X*-intercept of the linear portion of the graph, respectively. ER was calculated by dividing *J*~ss~ of the optimized ethosomal system by that of the unprocessed drug transdermal film. *K*~p~ was calculated using [Equation 2](#fd2-dddt-9-6129){ref-type="disp-formula"}. $$K_{p} = J_{\text{ss}}/C$$

*D* was calculated using [Equation 3](#fd3-dddt-9-6129){ref-type="disp-formula"}: $$T_{L} = h^{2}/6D$$where *h* is skin thickness, *T*~L~ is lag time, *C* is film initial concentration, and *D* is diffusion coefficient.

### Confocal laser scanning microscopy

For confocal laser scanning microscopy (CLSM), a fluorescent dye, Rhodamine B (Rh), with a concentration of 0.1% (w/v) was incorporated in the optimized VRD-NE. The fluorescent nanoethosomes were poured into the HPMC solution as described previously to form VRD-NE-HPMC film. Another HPMC film was formed with plain dye. The films were applied to the skin pieces. The procedure used for ex vivo permeation study was similar to that prescribed in the "Ex vivo skin permeation studies" section. After 1 and 4 hours, the skin was removed from the diffusion cells, rinsed with distilled water, and preserved in 10% (v/v) formalin in phosphate-buffered saline (pH 7.4) for 24 hours. The skin was vertically cross-sectioned into pieces of 0.5 mm^2^ size and evaluated for probe penetration. The full skin thickness was optically scanned. Visualization was performed by the ×10 objective lens system of an inverted Zeiss LSM 510 META microscope (Carl Zeiss, Jena, Germany), equipped with a He--Ne laser. The excitation wavelength used was 562 nm, while emission wavelength was 587 nm.[@b17-dddt-9-6129]

Bioavailability study
---------------------

All experimental protocols were approved by the Animal Ethics Committee of King Abdulaziz University, Jeddah, Saudi Arabia, and conformed to the Declaration of Helsinki and the Guiding Principle in Care and Use of Animals (DHEW publication NIH 80-23) and the "Principles of Laboratory Animal Care" (NIH publication \#85-23, revised in 1985). Male Wistar rats (350±50 g) were used for the pharmacokinetic study. The rats were acclimated for at least 7 days in environmentally controlled cages (23°C±1°C and 12/12 hour dark/light cycle) with free access to standard food and water. The rats were fasted overnight before the experiments. The animals were divided into two groups (four rats per group). The first group received an oral dose of VRD (2 mg/kg) suspended in water (1 mL). In the second group, a VRD-NE film was applied to a shaved patch on the back of the animal at a dose equivalent to 2 mg/kg VRD. Two hundred microliters of blood from each rat was withdrawn at 0, 1, 2, 4, 8, 12, 24, and 36 hours.

Pharmacokinetic parameters based on VRD plasma concentrations were analyzed with PK-SOLVER software using a noncompartmental model. Maximum plasma concentration (*C*~max~), time to maximum concentration (*T*~max~), area under the plasma concentration--time curve (AUC), and mean residency time (MRT) were calculated for individual rats.

Statistical analysis of data
----------------------------

Data are presented as mean ± standard deviation. Significant differences between the pharmacokinetic data were tested by analysis of variance followed by Tukey's multiple comparisons test; the confidence level was set at *P*\<0.05 (GraphPad Prism 6; GraphPad Software, La Jolla, CA, USA).

Quantification of VRD in plasma by HPLC-DAD detector
----------------------------------------------------

Plasma drug concentrations were analyzed using an Agilent HPLC instrument 1200 (Agilent Technologies, Santa Clara, CA, USA), with a 1200 diode array detector (DAD) detector set at a wavelength of 230 nm. An isocratic mobile phase (acetonitrile:potassium dihydrogen orthophosphate buffer, 10 mM \[1:1, v/v\], adjusted to pH 3 with orthophosphoric acid) was used for the elution. The separation was carried out using an ODS-A C18 analytical column (250 mm ×4.6 mm i.d., ACE Ltd, Zurich Switzerland), with a flow rate of 1.3 mL/min. The column was maintained at 40°C, and the injection volume was 20 µL. The HPLC conditions and VRD plasma extraction procedure were adapted from a method described by Carlucci et al.[@b16-dddt-9-6129]

Results and discussion
======================

A Box--Behnken design was used in this study to optimize a nanoethosomal film formulation of VRD. This approach proposed different formulations to enhance the clinical efficacy of VRD in treating ED, while reducing side effects commonly associated with PDE5 inhibitors. By using a Box--Behnken design, each independent variable was investigated at three levels, and the outcome was based on two responses, nanoethosomal vesicular size and EE. Optimized conditions were determined by experimentally testing the 15 formulations generated by the design. Pareto charts ([Figure 1](#f1-dddt-9-6129){ref-type="fig"}) were used to illustrate the effect of the experimental variables on the responses. A positive sign in the chart indicates a direct relationship between the variable and the observed response, whereas a negative sign indicates an inverse relationship.

Vesicle size
------------

The Pareto chart showed a significant inverse effect of both [l]{.smallcaps}-α-phosphatidylcholine and sonication time on vesicle size. The interaction of these variables and their quantitative effects on the observed responses were generated using a mathematical regression equation ([Equation 4](#fd4-dddt-9-6129){ref-type="disp-formula"}) for the observed response *Y*~1~. $$Y_{1} = 1,249.37 - 1.6321 \ast X_{1} - 205.712 \ast X_{2} - 12.2147 \ast X_{3} + 0.000967708 \ast X_{1}{}^{2} + 0.10125 \ast X_{1} \ast X_{2} + 0.0054 \ast X_{1} \ast X_{2} + 16.7396 \ast X_{2} + 0.305 \ast X_{2} \ast X_{3} + 0.0751333 \ast X_{3}{}^{2}$$

Several reports have demonstrated the importance of [l]{.smallcaps}-α-phosphatidylcholine on vesicular size in the preparation of NE. These reports describe the role of [l]{.smallcaps}-α-phosphatidylcholine, with a hydrophile--lipophile balance value of 4, as emulsifying agent.[@b18-dddt-9-6129] The vesicle size of NE decreased with increasing concentration of surfactant. All emulsifying agents concentrate at the aqueous:nonaqueous interface and provide a protective barrier around the dispersed droplets; emulsifiers stabilize the emulsion by reducing the interfacial tension of the system. Some agents enhance the stability by imparting a charge on the droplet surface, thus reducing the physical contact between the droplets and decreasing the potential for coalescence. In our experiments, however, increased amounts of CHO increased the ethosomal vesicle size, in agreement with data published by Essa.[@b19-dddt-9-6129] This effect may be attributed to the amphipathic nature of CHO, which has hydrophilic head (hydroxyl group) and a hydrophobic tail (hydrocarbon chain). When CHO is incorporated in the bilayer membrane, the hydrophilic head is oriented toward the aqueous phase, and the aliphatic tail lies parallel to the hydrocarbon chains. CHO is known to increase the chain order of the liquid-state bilayer and strengthen the nonpolar tail of the nonionic surfactant. Accordingly, at low CHO concentrations, it is expected that CHO would result in close packing of surfactant monomers, increased curvature, and reduced size of NE vesicles. Conversely, higher concentrations of lipophilic CHO (log *P* 7.02) would reduce the nonionic surfactant content, increase the hydrophobicity, and disturb the vesicular bilayer membrane, thus increasing the size of NE vesicles.[@b20-dddt-9-6129]

Sonication time is a significant variable affecting vesicle size (*P*=0.001; [Table 3](#t3-dddt-9-6129){ref-type="table"}). The use of different sonication times results in different vesicle sizes. Before sonication, large multi-lamellar vesicles with variable size distribution were produced. After ultrasonication, the vesicles were more homogenous, with reduced size because of intramembrane cavitation within the bilayer. Ultrasonic waves travel through globules and produce compression forces, called cavitation forces, which lead to fractionation of the original globule. These globular fractions transform into long tube-like appendages that can easily be pinched off into small globules.[@b21-dddt-9-6129]

Entrapment efficiency
---------------------

The Pareto chart shows a positive relationship between *X*~1~ and EE. Increasing amounts of ethanol were found to have a significant negative effect on VRD EE. The interaction of these factors and their quantitative effects on the responses were generated using a mathematical regression equation for the observed response, *Y*~2~ ([Equation 5](#fd5-dddt-9-6129){ref-type="disp-formula"}). $$Y_{2} = 52.7269 + 0.09175 \ast X_{1} + 3.88525 \ast X_{2} - 1.33642 \ast X_{3} + 0.00008075 \ast X_{1}{}^{2} + 0.003125 \ast X_{1} \ast X_{2} - 0.00105 \ast X_{1} \ast X_{2} + 0.005 \ast X_{1}{}^{2} - 0.0568 \ast X_{2} \ast X_{3} + 0.010432 \ast X_{3}{}^{2}$$

The estimated response surface plots ([Figure 2](#f2-dddt-9-6129){ref-type="fig"}) reveal the relationship between dependent and independent variables. The optimized VRD-NE formulation was prepared using predicted values of *X*~1~, *X*~2~, and *X*~3~ to measure the observed responses and compare with the calculated values.

The positive relationship between *X*~1~ and EE can be explained by the emulsification effect of [l]{.smallcaps}-α-phosphatidylcholine, which decreases interfacial tension between the two phases leading to a homogeneous and stable emulsion. This then enhances VRD entrapment in the NE vesicles. These results are in agreement with data published by Dave et al. Similarly, increasing CHO concentrations could exclude VRD because of competition between CHO and VRD for packing space within the vesicular NE bilayer.[@b22-dddt-9-6129] According to El-Samaligy et al, increasing the CHO concentration leads to loss of vesicular membrane linearity and disturbs the membrane structure.[@b23-dddt-9-6129]

Increasing amounts of ethanol were found to have a significant negative effect on VRD EE. This can be attributed to the solubility of both VRD and [l]{.smallcaps}-α-phosphatidylcholine in ethanol and their insolubility in water. Increased ethanol in the hydration medium will thus solubilize the drug and increase the amount of free VRD in the hydration medium. Sonication time was shown to be a nonsignificant variable (*P*=0.46). The positive effect of sonication time may be attributed to the enhanced mobility of the surfactant. Rearrangement of lipid molecules also allows for higher entrapment of the drug, with redistribution of the drug inside the NE vesicles.[@b24-dddt-9-6129]

The observed and predicted values together with residuals for the optimized formulation are shown in [Table 4](#t4-dddt-9-6129){ref-type="table"}.

VRD-NE vesicle morphology
-------------------------

The transmission electron microscopy image of the optimized VRD-NE formulation shows a vesicular structure with spherical shape and homogenous unilamellar arrangement ([Figure 3](#f3-dddt-9-6129){ref-type="fig"}). The effect of ethanol on vesicle shape is as observed earlier by Touitou et al.[@b25-dddt-9-6129] An ethanol concentration of 20%--50% arranges the ethosomal phospholipid in the form of a tightly packed bilayer with a closed configuration. This can be rationalized by hypothesizing that the motion of the polar head groups of the ethosomal phospholipids is less restricted in the presence of alcohol than in the absence of alcohol. At 50% ethanol concentration, the signal becomes isotropic and narrow, showing that the phospholipid exists as small, fast-tumbling vesicles. Optimized formula was immediately added to HPMC film solution, so zeta potential (charges which cover the ethosomes) was not considered as an effective parameter or a valuable indicator of stability data in this work.

Drug diffusion
--------------

Comparative permeation profiles of optimized VRD-NE films and unprocessed VRD films are depicted in [Figure 4](#f4-dddt-9-6129){ref-type="fig"}. There was a dramatic rapid diffusion of VRD (\~30%) after 1 hour from the optimized NE film; diffusion from the unprocessed drug film did not exceed 4% after 1 hour. The optimized formulation showed significantly (*P*\<0.05) enhanced transdermal flux (6.16±2.12 ng/cm·h) across rat skin compared with unprocessed drug film (3.56±1.32 ng/cm^2^·h). Skin permeation parameters which were calculated from the skin permeation data are shown in [Table 5](#t5-dddt-9-6129){ref-type="table"}, that are attributed to the effect of ethanol, which acts as penetration enhancer in skin by increasing the fluidity of cell membrane lipids and decreasing the density of cell membrane lipids.[@b26-dddt-9-6129] The improved diffusion of the VRD-NE film may also have been facilitated by fusion of ethosomal phospholipids with skin lipids, thereby facilitating VRD-NE permeation into deep skin layers.[@b27-dddt-9-6129]

CLSM images
-----------

The CLSM study was also conducted to confirm the skin penetration of the vesicles. Top view or *x*--*y* plane images of rat skin treated with Rh-labeled HPMC films at varying time periods are presented in [Figure 5](#f5-dddt-9-6129){ref-type="fig"}. Auto fluorescence of the skin (orange) is shown in [Figure 5](#f5-dddt-9-6129){ref-type="fig"}. At 1 hour, HPMC plain film was deposited with a very low intensity at the dermis layer ([Figure 5](#f5-dddt-9-6129){ref-type="fig"}), while VRD-NE were deposited in both the skin surface and the epidermis ([Figure 5](#f5-dddt-9-6129){ref-type="fig"}). Fluorescence intensity from vesicles was high. Because the vesicles were more lipophilic than the plain dye, these vesicles could penetrate into the skin with a higher skin permeation rate than HPMC plain film. At 4 hours, plain HPMC was deposited with a low intensity with traces of orange fluorescence in hypodermis layer, while the orange fluorescence intensity in the case of VRD-NE-HPMC film ([Figure 5](#f5-dddt-9-6129){ref-type="fig"}) was high especially in dermis and hypodermis layers that could be because ethanolic aqueous core could penetrate through the skin.

Bioavailability study
---------------------

The AUC for the VRD-NE formulation was 271.67 ng/mL·h, which was significantly (*P*\<0.05) improved compared with the oral drug suspension (128.30 ng/mL·h). A significant (*P*\<0.05) augmentation of *C*~max~ was observed with the VRD-NE transdermal film compared with the aqueous suspension. Plasma concentration--time profiles for VRD after transdermal administration of the ethosomal formulation and oral administration of a VRD suspension are shown in [Figure 6](#f6-dddt-9-6129){ref-type="fig"}. Pharmacokinetic parameters are shown in [Table 6](#t6-dddt-9-6129){ref-type="table"}. The enhanced bioavailability following transdermal administration of the liposomal formulation can be attributed to a combination of factors: firstly, the ethosomal vesicles act as a delivery vector for VRD to cross skin barriers; secondly, the ethosomal vesicles introduce VRD as a fine dispersion compared with the coarser particles of the VRD oral suspension, and provide an increased surface area with a reduced diffusion path length; and thirdly, the NE vesicles afford a higher adhesion surface contact with the absorption site. The MRT for the VRD-NE film (16.84±3.54 hours) was higher than that of the VRD oral suspension (7.24±2.32 hours). This suggests that VRD-NE are retained within the skin layers for longer periods of time and serve as a drug reservoir for extended release into the viable epidermis.

Conclusion
==========

An optimized nanoethosomal system for transdermal delivery of VRD has been developed to treat ED and evaluated both ex vivo and in vivo. In the preparation of VRD as nanoethosomal vesicles, addition of CHO, and the use of a more rigid phospholipid with an ethanolic aqueous core improved VRD EE within the vesicles. Pharmacokinetic studies in rats showed approximately twofold augmentation of VRD bioavailability from the transdermal films compared with an oral drug suspension. VRD-NE transdermal films could thus be used to treat ED, with the potential for lower doses and reduced side effects. VRD-NE transdermal films are a promising transdermal drug delivery system for the treatment of ED that could improve patient tolerability and compliance.
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![Standard Pareto charts showing the effects of independent variables and their combined effects on particle size (**A**) and VRD EE (**B**).\
**Abbreviations:** VRD, vardenafil; EE, encapsulation efficiency; *X*~1~, % [l]{.smallcaps}-α-phosphatidylcholine to total lipids; *X*~2~, ultrasonication time (minutes); *X*~3~, % ethanol in the hydration medium.](dddt-9-6129Fig1){#f1-dddt-9-6129}

![The effects of independent variables and their combined effects on *Y*~1~ and *Y*~2~ are represented as 3D response surface plots.\
**Abbreviations:** *Y*~1~, mean particle size; *Y*~2~, vardenafil encapsulation efficiency.](dddt-9-6129Fig2){#f2-dddt-9-6129}

![TEM image of optimized VRD-NE.\
**Abbreviations:** TEM, transmission electron microscopy; VRD-NE, vardenafil nanoethosomes.](dddt-9-6129Fig3){#f3-dddt-9-6129}

![Percentage of cumulative VRD permeation from VRD-NE film and from VRD aqueous suspension through skin.\
**Abbreviations:** VRD, vardenafil; VRD-NE, vardenafil nanoethosomes.](dddt-9-6129Fig4){#f4-dddt-9-6129}

![Confocal laser scanning microscopic images.\
**Abbreviations:** HPMC, hydroxypropyl methylcellulose; VRD-NE-HPMC, vardenafil nanoethosomes with hydroxypropyl methylcellulose.](dddt-9-6129Fig5){#f5-dddt-9-6129}

![Mean ± SD plasma concentrations for VRD-NE film and VRD aqueous suspension.\
**Abbreviations:** SD, standard deviation; VRD-NE, vardenafil nanoethosomes; VRD, vardenafil; conc, concentrations.](dddt-9-6129Fig6){#f6-dddt-9-6129}

###### 

Independent and dependent variables and their levels for Box--Behnken design

  Factors   Levels   Constraints                                 
  --------- -------- ------------- ---- -------- ------- ------- ----------
  *X*~1~    10       50            90   *Y*~1~   98      543     Minimize
  *X*~2~    1        3             5                             
  *X*~3~    30       55            80   *Y*~2~   10.12   78.76   Maximize

**Abbreviations:** *X*~1~, % [l]{.smallcaps}-α-phosphatidylcholine to total lipids; *X*~2~, ultrasonication time (minutes); *X*~3~, % ethanol in the hydration medium; *Y*~1~, mean particle size; *Y*~2~, vardenafil encapsulation efficiency.

###### 

Experimental runs and their observed responses

  Run   Factors   Responses              
  ----- --------- ----------- ---- ----- -------
  1     90        3           30   213   78.76
  2     10        5           55   324   26.34
  3     10        3           30   432   27.53
  4     90        5           55   132   55.34
  5     50        3           55   231   43.34
  6     50        5           80   98    13.42
  7     90        3           80   176   40.32
  8     10        3           80   287   10.12
  9     50        3           55   178   21.93
  10    10        1           55   165   23.54
  11    90        1           55   541   12.01
  12    50        3           55   189   36.42
  13    50        1           30   543   52.53
  14    50        5           30   145   53.76
  15    50        1           80   435   23.21

**Note:**

SD values were \<5%.

**Abbreviations:** SD, standard deviation; *X*~1~, % [l]{.smallcaps}-α-phosphatidylcholine to total lipids; *X*~2~, ultrasonication time (minutes); *X*~3~, % ethanol in the hydration medium; *Y*~1~, mean particle size; *Y*~2~, vardenafil encapsulation efficiency.

###### 

Estimated effects and associated *P*-values for all three responses

  Factor         Response                                                                
  -------------- ---------- --------------------------------------------------- -------- ----------------------------------------------------
  *X*~1~         --         0.044[\*](#tfn4-dddt-9-6129){ref-type="table-fn"}   33.5     0.0083[\*](#tfn4-dddt-9-6129){ref-type="table-fn"}
  *X*~2~         −303.5     0.001[\*](#tfn4-dddt-9-6129){ref-type="table-fn"}   6.29     0.46
  *X*~3~         −34.75     0.47                                                −31.09   0.011[\*](#tfn4-dddt-9-6129){ref-type="table-fn"}
  *X*~1~^2^      −22.833    0.74                                                6.46     0.60
  *X*~1~*X*~2~   182.5      0.031[\*](#tfn4-dddt-9-6129){ref-type="table-fn"}   2.5      0.83
  *X*~1~*X*~3~   45.0       0.507                                               −10.5    0.39
  *X*~2~^2^      132.66     0.099                                               0.04     0.99
  *X*~2~*X*~3~   30.5       0.64                                                −5.68    0.63
  *X*~3~^2^      95.16      0.20                                                13.04    0.31

**Note:**

Significant effect of factors on individual responses.

**Abbreviations:** *X*~1~, % [l]{.smallcaps}-α-phosphatidylcholine to total lipids; *X*~2~, ultrasonication time (minutes); *X*~3~, % ethanol in the hydration medium; *Y*~1~, mean particle size; *Y*~2~, vardenafil encapsulation efficiency.

###### 

Predicted and observed values for the optimized VRD-NE

  Factors   Level   Responses   Predicted   Observed
  --------- ------- ----------- ----------- ----------
  *X*~1~    90      *Y*~1~      133         128
  *X*~2~    4.72    *Y*~2~      78.00       76.23
  *X*~3~    33.21   --          --          --

**Abbreviations:** VRD-NE, vardenafil nanoethosomes; *X*~1~, % [l]{.smallcaps}-α-phosphatidyl-choline to total lipids; *X*~2~, ultrasonication time (minutes); *X*~3~, % ethanol in the hydration medium; *Y*~1~, mean particle size; *Y*~2~, vardenafil encapsulation efficiency.

###### 

Skin permeation parameters of VRD from nanoethosomal film and VRD raw film through rat abdominal skin

  Parameter                     Unit         VRD raw film   VRD-NE formula film
  ----------------------------- ------------ -------------- ---------------------------------------------------------
  Steady-state flux             ng/cm^2^·h   3.56±1.32      6.16±2.12[\*](#tfn7-dddt-9-6129){ref-type="table-fn"}
  Permeability coefficient      cm/h         0.005±0.001    0.01±0.003
  Diffusion coefficient (*D*)   cm^2^/h      0.001±0.002    0.004±0.001[\*](#tfn7-dddt-9-6129){ref-type="table-fn"}
  Enhancement ratio             --           --             3.05

**Note:**

Significant variance (*P*-value \<0.05).

**Abbreviations:** VRD, vardenafil; VRD-NE, vardenafil nanoethosomes.

###### 

Pharmacokinetic parameters of VRD-NE after transdermal administration of 2 mg/kg optimized formula and 2 mg/kg of VRD aqueous suspension

  Parameter         Unit      VRD suspension   VRD-transdermal nanoethosomes
  ----------------- --------- ---------------- ----------------------------------------------------------
  *t*~1/2~          hours     3.89±1.23        14.40±4.54[\*](#tfn9-dddt-9-6129){ref-type="table-fn"}
  *T*~max~          hours     4±10             2±1.54
  *C*~max~          ng/mL     14.54±6.32       25.76±5.39
  AUC~0--inf_obs~   ng/mL·h   128.30±18.87     271.67±37.43[\*](#tfn9-dddt-9-6129){ref-type="table-fn"}
  MRT~0--inf_obs~   hours     7.24±2.32        16.84±3.54[\*](#tfn9-dddt-9-6129){ref-type="table-fn"}

**Note:**

Significant variance (*P*-value \<0.05).

**Abbreviations:** VRD-NE, vardenafil nanoethosomes; VRD, vardenafil; AUC, area under the plasma concentration--time curve; MRT, mean residency time; *t*~1/2~, half life; *T*~max~, time of maximum concentration; *C*~max~, maximum concentration.
